{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "05",
                "@year": "2023",
                "@timestamp": "2023-07-05T15:45:31.000031-04:00",
                "@month": "07"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2021",
                "@month": "01"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": {"xocs:funding-agency-matched-string": "Dr Reddy\u2019s Laboratories Ltd."},
            "xocs:funding-addon-generated-timestamp": "2022-06-11T15:59:48.833Z",
            "xocs:funding-text": "The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Medical writing support in the preparation of this article was provided by Tarveen Jandoo. Financial support was provided by an educational grant from Dr Reddy\u2019s Laboratories Ltd. Hyderabad.",
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "Brazil",
                            "@country": "bra",
                            "city": "Sao Paulo",
                            "organization": [
                                {"$": "Department of Medical Oncology"},
                                {"$": "Beneficencia Portuguesa de Sao Paulo"}
                            ],
                            "@affiliation-instance-id": "2010567845-70ea51055477b1536a1c87904166b3cf",
                            "ce:source-text": "Department of Medical Oncology, Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil"
                        },
                        "author": [{
                            "ce:given-name": "Fabio Augusto Barros",
                            "preferred-name": {
                                "ce:given-name": "Fabio Augusto Barros",
                                "ce:initials": "F.A.B.",
                                "ce:surname": "Schutz",
                                "ce:indexed-name": "Schutz F.A.B."
                            },
                            "@seq": "1",
                            "@author-instance-id": "2010567845-b63231c1e666d052f68f6006b46b0ed9",
                            "ce:initials": "F.A.B.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Schutz",
                            "@auid": "35181986100",
                            "ce:indexed-name": "Schutz F.A.B."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60199578",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": {"$": "Ramathibodi Hospital"},
                            "affiliation-id": {"@afid": "60199578"},
                            "@affiliation-instance-id": "2010567845-d43505403f2a5b9f0cdeedfcbb1966bc",
                            "ce:source-text": "Ramathibodi Hospital, Bangkok, Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Ekaphop",
                            "preferred-name": {
                                "ce:given-name": "Ekaphop",
                                "ce:initials": "E.",
                                "ce:surname": "Sirachainan",
                                "ce:indexed-name": "Sirachainan E."
                            },
                            "@seq": "2",
                            "@author-instance-id": "2010567845-7c0069b45b6384f481eaa92f38775a0c",
                            "ce:initials": "E.",
                            "@date-locked": "2023-01-17T07:05:37.814",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Sirachainan",
                            "@auid": "6602792356",
                            "ce:indexed-name": "Sirachainan E."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Malaysia",
                            "@afid": "60013665",
                            "@country": "mys",
                            "city": "Kuala Lumpur",
                            "organization": [
                                {"$": "Consultant Urologist"},
                                {"$": "Department of Surgery"},
                                {"$": "University Malaya Medical Centre"}
                            ],
                            "affiliation-id": {
                                "@afid": "60013665",
                                "@dptid": "125810303"
                            },
                            "@affiliation-instance-id": "2010567845-9f283da6930af4a04ad607dd6ecbf8b5",
                            "ce:source-text": "Consultant Urologist, Department of Surgery, University Malaya Medical Centre, Kuala Lumpur, Malaysia",
                            "@dptid": "125810303"
                        },
                        "author": [{
                            "ce:given-name": "Shanggar",
                            "preferred-name": {
                                "ce:given-name": "Shanggar",
                                "ce:initials": "S.",
                                "ce:surname": "Kuppusamy",
                                "ce:indexed-name": "Kuppusamy S."
                            },
                            "@seq": "3",
                            "@author-instance-id": "2010567845-484d16d748c0f247667042b9ade181e0",
                            "ce:initials": "S.",
                            "@date-locked": "2022-12-27T12:33:57.542",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Kuppusamy",
                            "@auid": "36115254700",
                            "ce:indexed-name": "Kuppusamy S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Viet Nam",
                            "@afid": "100787418",
                            "@country": "vnm",
                            "city": "Hanoi",
                            "organization": [
                                {"$": "Department of Medical Oncology"},
                                {"$": "National Cancer Hospital"}
                            ],
                            "affiliation-id": {
                                "@afid": "100787418",
                                "@dptid": "114366172"
                            },
                            "@affiliation-instance-id": "2010567845-c170c488365ec285d13894728a73e77f",
                            "ce:source-text": "Department of Medical Oncology, National Cancer Hospital, Hanoi, Vietnam",
                            "@dptid": "114366172"
                        },
                        "author": [
                            {
                                "ce:given-name": "Nguyen Thi Thai",
                                "preferred-name": {
                                    "ce:given-name": "Nguyen Thi Thai",
                                    "ce:initials": "N.T.T.",
                                    "ce:surname": "Hoa",
                                    "ce:indexed-name": "Hoa N.T.T."
                                },
                                "@seq": "4",
                                "@author-instance-id": "2010567845-e9519f45cc18f71368b4628a9285627e",
                                "ce:initials": "N.T.T.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Hoa",
                                "@auid": "57222117474",
                                "ce:indexed-name": "Hoa N.T.T."
                            },
                            {
                                "ce:given-name": "Vu Quang",
                                "preferred-name": {
                                    "ce:given-name": "Vu Quang",
                                    "ce:initials": "V.Q.",
                                    "ce:surname": "Toan",
                                    "ce:indexed-name": "Toan V.Q."
                                },
                                "@seq": "7",
                                "@author-instance-id": "2010567845-67732973d1409cbf3c417103405914a5",
                                "ce:initials": "V.Q.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Toan",
                                "@auid": "57222119567",
                                "ce:indexed-name": "Toan V.Q."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60199578",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Medical Oncologist"},
                                {"$": "Ramathibodi Hospital"}
                            ],
                            "affiliation-id": {"@afid": "60199578"},
                            "@affiliation-instance-id": "2010567845-7dc38654b3b1026c133e17e5c89e7584",
                            "ce:source-text": "Medical Oncologist, Ramathibodi Hospital, Bangkok, Thailand"
                        },
                        "author": [
                            {
                                "ce:given-name": "Thitiya",
                                "preferred-name": {
                                    "ce:given-name": "Thitiya",
                                    "ce:initials": "T.",
                                    "ce:surname": "Dejthevaporn",
                                    "ce:indexed-name": "Dejthevaporn T."
                                },
                                "@seq": "5",
                                "@author-instance-id": "2010567845-7a6c8bd2df559a6147f693fe0191464d",
                                "ce:initials": "T.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Dejthevaporn",
                                "@auid": "57202709168",
                                "ce:indexed-name": "Dejthevaporn T."
                            },
                            {
                                "ce:given-name": "Phichai",
                                "preferred-name": {
                                    "ce:given-name": "Phichai",
                                    "ce:initials": "P.",
                                    "ce:surname": "Chansriwong",
                                    "ce:indexed-name": "Chansriwong P."
                                },
                                "@seq": "8",
                                "@author-instance-id": "2010567845-a17dc23bcef3c7f8bb0c84e4c411b8bf",
                                "ce:initials": "P.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Chansriwong",
                                "@auid": "37007308200",
                                "ce:indexed-name": "Chansriwong P."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Malaysia",
                            "@afid": "121444563",
                            "@country": "mys",
                            "city": "Selangor",
                            "organization": [
                                {"$": "Consultant Urologist"},
                                {"$": "Sunway Medical Centre"}
                            ],
                            "affiliation-id": {
                                "@afid": "121444563",
                                "@dptid": "125809999"
                            },
                            "@affiliation-instance-id": "2010567845-4b74635d4e6d69fbaeced1e1393f09e0",
                            "ce:source-text": "Consultant Urologist, Sunway Medical Centre, Selangor, Malaysia",
                            "@dptid": "125809999"
                        },
                        "author": [{
                            "ce:given-name": "Badrulhisham",
                            "preferred-name": {
                                "ce:given-name": "Badrulhisham",
                                "ce:initials": "B.",
                                "ce:surname": "Bahadzor",
                                "ce:indexed-name": "Bahadzor B."
                            },
                            "@seq": "6",
                            "@author-instance-id": "2010567845-ab7408a88a5dd671a0c95633d09c386f",
                            "ce:initials": "B.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Bahadzor",
                            "@auid": "54787296900",
                            "ce:indexed-name": "Bahadzor B."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Malaysia",
                            "@afid": "60013665",
                            "@country": "mys",
                            "city": "Kuala Lumpur",
                            "organization": [
                                {"$": "Clinical Oncology Unit"},
                                {"$": "University Malaya Medical Centre"}
                            ],
                            "affiliation-id": {
                                "@afid": "60013665",
                                "@dptid": "109279776"
                            },
                            "@affiliation-instance-id": "2010567845-bdb48bc3c86eab27d18c36892b14a9cc",
                            "ce:source-text": "Clinical Oncology Unit, University Malaya Medical Centre, Kuala Lumpur, Malaysia",
                            "@dptid": "109279776"
                        },
                        "author": [{
                            "ce:given-name": "Adlinda",
                            "preferred-name": {
                                "ce:given-name": "Adlinda",
                                "ce:initials": "A.",
                                "ce:surname": "Alip",
                                "ce:indexed-name": "Alip A."
                            },
                            "@seq": "9",
                            "@author-instance-id": "2010567845-c1bddd5d58bf8bcb8880cb816e6fa888",
                            "ce:initials": "A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Alip",
                            "@auid": "56495291900",
                            "ce:indexed-name": "Alip A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Viet Nam",
                            "@afid": "60071389",
                            "@country": "vnm",
                            "city": "Ho Chi Minh City",
                            "organization": [
                                {"$": "Department of Medical and Radiation Oncology"},
                                {"$": "Cho Ray Hospital"}
                            ],
                            "affiliation-id": {
                                "@afid": "60071389",
                                "@dptid": "125810797"
                            },
                            "@affiliation-instance-id": "2010567845-f8cdb62e87b6ff1bd3a7fcc8c2f755f8",
                            "ce:source-text": "Department of Medical and Radiation Oncology, Cho Ray Hospital, Ho Chi Minh City, Việt Nam",
                            "@dptid": "125810797"
                        },
                        "author": [{
                            "ce:given-name": "Nguyen Thi Minh",
                            "preferred-name": {
                                "ce:given-name": "Nguyen Thi Minh",
                                "ce:initials": "N.T.M.",
                                "ce:surname": "Hue",
                                "ce:indexed-name": "Hue N.T.M."
                            },
                            "@seq": "10",
                            "@author-instance-id": "2010567845-912d0ecd2fd5a470c49c16ce7e2327be",
                            "ce:initials": "N.T.M.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Hue",
                            "@auid": "57222128661",
                            "ce:indexed-name": "Hue N.T.M."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60022183",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Medical Oncologist"},
                                {"$": "Chulalongkorn Hospital"}
                            ],
                            "affiliation-id": {"@afid": "60022183"},
                            "@affiliation-instance-id": "2010567845-f7cfe29ec9ee615a62d5a26413b78f9b",
                            "ce:source-text": "Medical Oncologist, Chulalongkorn Hospital, Bangkok, Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Napa",
                            "preferred-name": {
                                "ce:given-name": "Napa",
                                "ce:initials": "N.",
                                "ce:surname": "Parinyanitikul",
                                "ce:indexed-name": "Parinyanitikul N."
                            },
                            "@seq": "11",
                            "@author-instance-id": "2010567845-6969a4c6e90d1af488710a76e953f820",
                            "ce:initials": "N.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Parinyanitikul",
                            "@auid": "36554719100",
                            "ce:indexed-name": "Parinyanitikul N."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Malaysia",
                            "@afid": "60103837",
                            "@country": "mys",
                            "organization": [
                                {"$": "Consultant Oncologist"},
                                {"$": "Hospital Pulau Pinang"}
                            ],
                            "affiliation-id": {
                                "@afid": "60103837",
                                "@dptid": "125810919"
                            },
                            "@affiliation-instance-id": "2010567845-28e5cae07a624e3d0479a1a6c7cb813b",
                            "ce:source-text": "Consultant Oncologist, Hospital Pulau Pinang, Malaysia",
                            "@dptid": "125810919"
                        },
                        "author": [{
                            "ce:given-name": "Ai Lian",
                            "preferred-name": {
                                "ce:given-name": "Ai Lian",
                                "ce:initials": "A.L.",
                                "ce:surname": "Tan",
                                "ce:indexed-name": "Tan A.L."
                            },
                            "@seq": "12",
                            "@author-instance-id": "2010567845-de04a62e42f112d5556b632b20d7388c",
                            "ce:initials": "A.L.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Tan",
                            "@auid": "55585808300",
                            "ce:indexed-name": "Tan A.L."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Viet Nam",
                            "@afid": "107981430",
                            "@country": "vnm",
                            "organization": {"$": "Ho Chi Minh City Oncology Hospital"},
                            "affiliation-id": {"@afid": "107981430"},
                            "@affiliation-instance-id": "2010567845-2d351bfe8433edb42059592c02082e06",
                            "ce:source-text": "Ho Chi Minh City Oncology Hospital, Việt Nam"
                        },
                        "author": [{
                            "ce:given-name": "Vu Dinh Khanh",
                            "preferred-name": {
                                "ce:given-name": "Vu Dinh Khanh",
                                "ce:initials": "V.D.K.",
                                "ce:surname": "Hoang",
                                "ce:indexed-name": "Hoang V.D.K."
                            },
                            "@seq": "13",
                            "@author-instance-id": "2010567845-3459479e05a4bccaabb64e87edad928a",
                            "ce:initials": "V.D.K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Hoang",
                            "@auid": "57222132081",
                            "ce:indexed-name": "Hoang V.D.K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60005255",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Medical Oncologist"},
                                {"$": "Rajavithi Hospital"}
                            ],
                            "affiliation-id": {"@afid": "60005255"},
                            "@affiliation-instance-id": "2010567845-5f0a165f8efa8a7039995b66e02d07ec",
                            "ce:source-text": "Medical Oncologist, Rajavithi Hospital, Bangkok, Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Piyawan",
                            "preferred-name": {
                                "ce:given-name": "Piyawan",
                                "ce:initials": "P.",
                                "ce:surname": "Tienchaiananda",
                                "ce:indexed-name": "Tienchaiananda P."
                            },
                            "@seq": "14",
                            "@author-instance-id": "2010567845-dff1f372cc34610679801798d52ac3e4",
                            "ce:initials": "P.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Tienchaiananda",
                            "@auid": "56705450700",
                            "ce:indexed-name": "Tienchaiananda P."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "India",
                            "address-part": "8-2-337, Road No. 3, Banjara Hills",
                            "postal-code": "500034",
                            "@afid": "60017484",
                            "@country": "ind",
                            "city": "Hyderabad",
                            "organization": {"$": "Dr. Reddy\u2019s Laboratories Ltd"},
                            "affiliation-id": {"@afid": "60017484"},
                            "@affiliation-instance-id": "2010567845-2c6fc17431fb40bb5066b462b686c097",
                            "ce:source-text": "Dr. Reddy\u2019s Laboratories Ltd, 8-2-337, Road No. 3, Banjara Hills, Hyderabad, 500034, India"
                        },
                        "author": [{
                            "ce:given-name": "Sai Naga Deepak",
                            "preferred-name": {
                                "ce:given-name": "Sai Naga Deepak",
                                "ce:initials": "S.N.D.",
                                "ce:surname": "Chinchapattanam",
                                "ce:indexed-name": "Chinchapattanam S.N.D."
                            },
                            "@seq": "15",
                            "@author-instance-id": "2010567845-97ccff1036203f9a71a1c36b074cd880",
                            "ce:initials": "S.N.D.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Chinchapattanam",
                            "@auid": "57222123023",
                            "ce:indexed-name": "Chinchapattanam S.N.D."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "India",
                            "@afid": "60017484",
                            "@country": "ind",
                            "city": "Hyderabad",
                            "organization": [
                                {"$": "Dr Reddy\u2019s Laboratories Ltd"},
                                {"$": "Global Medical Affairs"}
                            ],
                            "affiliation-id": {
                                "@afid": "60017484",
                                "@dptid": "109726081"
                            },
                            "@affiliation-instance-id": "2010567845-2a5e0dcb4c477d626a2e259dc016e23e",
                            "ce:source-text": "Dr Reddy\u2019s Laboratories Ltd, Global Medical Affairs, Hyderabad, India",
                            "@dptid": "109726081"
                        },
                        "author": [{
                            "ce:given-name": "Amit",
                            "preferred-name": {
                                "ce:given-name": "Amit",
                                "ce:initials": "A.",
                                "ce:surname": "Garg",
                                "ce:indexed-name": "Garg A."
                            },
                            "@seq": "16",
                            "@author-instance-id": "2010567845-58dacde4ab6b433bf9dc5983e1e16df2",
                            "ce:initials": "A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Garg",
                            "@auid": "57192432999",
                            "ce:indexed-name": "Garg A."
                        }]
                    }
                ],
                "citation-title": "Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel",
                "abstracts": "© The Author(s), 2021.Aims: Clinical decision making is challenging in men with metastatic prostate cancer (mPC), as heterogeneity in treatment options and patient characteristics have resulted in multiple scenarios with little or no evidence. The South East Asia Expert Panel 2019 addressed some of these challenges. Methods: Based on evidence in the literature and expert interviews, 19 statements were formulated for key challenges in the treatment of men with castration-sensitive and -resistant prostate cancer in clinical practice. A modified Delphi process was used to reach consensus among experts in the panel and develop clinical practice recommendations. Results: The majority of the panel preferred a risk-based stratification and recommended abiraterone or enzalutamide as first-line therapy for symptomatic chemotherapy naïve patients. Abiraterone is preferred over enzalutamide as a first-line treatment in these patients. However, the panel did not support the use of abiraterone in high risk lymph-node positive only (N+M0) or in non-metastatic (N0M0) patients. In select patients, low dose abiraterone with food may be used to optimize clinical outcomes. Androgen receptor gene splice variant status may be a useful guide to therapy. In addition, generic versions of approved therapies may improve access to treatment to a broader patient population. The choice of treatment, as well as sequencing are guided by both patient and disease characteristics, preferences, drug access, cost, and compliance. Conclusion: Expert recommendations are key to guidance for the optimal management of mPC. Appropriate choice, timing, and sequence of treatment options can help to tailor therapy to maximize outcomes in men with mPC.",
                "correspondence": {
                    "affiliation": {
                        "country": "India",
                        "address-part": "8-2-337, Road No. 3, Banjara Hills",
                        "postal-code": "500034",
                        "@country": "ind",
                        "city": "Hyderabad",
                        "organization": {"$": "Dr. Reddy\u2019s Laboratories Ltd"},
                        "ce:source-text": "Dr. Reddy\u2019s Laboratories Ltd, 8-2-337, Road No. 3, Banjara Hills, Hyderabad, 500034, India"
                    },
                    "person": {
                        "ce:given-name": "Sai Naga Deepak",
                        "ce:initials": "S.N.D.",
                        "ce:surname": "Chinchapattanam",
                        "ce:indexed-name": "Chinchapattanam S.N.D."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "abiraterone",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "chemotherapy",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "docetaxel",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "enzalutamide",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "metastatic prostate cancer",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "re"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "sourcetitle-abbrev": "Ther. Adv. Med. Oncol.",
                    "website": {"ce:e-address": {
                        "$": "http://tam.sagepub.com/content/by/year",
                        "@type": "email"
                    }},
                    "@country": "usa",
                    "translated-sourcetitle": {
                        "$": "Therapeutic Advances in Medical Oncology",
                        "@xml:lang": "eng"
                    },
                    "issn": [
                        {
                            "$": "17588359",
                            "@type": "electronic"
                        },
                        {
                            "$": "17588340",
                            "@type": "print"
                        }
                    ],
                    "volisspag": {"voliss": {"@volume": "13"}},
                    "@type": "j",
                    "publicationyear": {"@first": "2021"},
                    "publisher": {"publishername": "SAGE Publications Inc."},
                    "sourcetitle": "Therapeutic Advances in Medical Oncology",
                    "@srcid": "19700175160",
                    "publicationdate": {
                        "year": "2021",
                        "date-text": {
                            "@xfab-added": "true",
                            "$": "2021"
                        }
                    }
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "16",
                                    "classification-description": "Cancer"
                                },
                                {
                                    "classification-code": "28",
                                    "classification-description": "Urology and Nephrology"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": "2730"
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "chemicalgroup": {"chemicals": {
                        "@source": "esbd",
                        "chemical": [
                            {
                                "cas-registry-number": "154229-19-3",
                                "chemical-name": "abiraterone"
                            },
                            {
                                "cas-registry-number": "154229-18-2",
                                "chemical-name": "abiraterone acetate"
                            },
                            {
                                "cas-registry-number": "114977-28-5",
                                "chemical-name": "docetaxel"
                            },
                            {
                                "cas-registry-number": "915087-33-1",
                                "chemical-name": "enzalutamide"
                            },
                            {
                                "cas-registry-number": "53-03-2",
                                "chemical-name": "prednisone"
                            }
                        ]
                    }}
                },
                "grantlist": {
                    "@complete": "y",
                    "grant-text": {
                        "$": "All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work, and have given final approval for the version to be published. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Medical writing support in the preparation of this article was provided by Tarveen Jandoo. Financial support was provided by an educational grant from Dr Reddy\u2019s Laboratories Ltd. Hyderabad.",
                        "@xml:lang": "eng"
                    }
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2021 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "NURSNG"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "24",
                    "@year": "2021",
                    "@timestamp": "BST 05:38:59",
                    "@month": "03"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2010567845",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "931629596",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20210213538",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "2021098326",
                            "@idtype": "NURSNG"
                        },
                        {
                            "$": "20210932999",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20210665320",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "20210514574862",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85101563160",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85101563160",
                            "@idtype": "SGR"
                        }
                    ],
                    "ce:doi": "10.1177/1758835920985464"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "64",
                "reference": [
                    {
                        "ref-fulltext": "Ogden SR, Culp WC, JrVillamaria FJ, et al. Developing a checklist: consensus via a modified Delphi technique. J Cardiothorac Vasc Anesth 2016; 30: 855\u2013858.",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Developing a checklist: consensus via a modified Delphi technique"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr1-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84975154485",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "30"},
                                "pagerange": {
                                    "@first": "855",
                                    "@last": "858"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Ogden",
                                        "ce:indexed-name": "Ogden S.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "W.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Culp",
                                        "ce:suffix": "Jr.",
                                        "ce:indexed-name": "Culp W.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Villamaria",
                                        "ce:indexed-name": "Villamaria F.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Cardiothorac Vasc Anesth"
                        },
                        "ce:source-text": "Ogden SR, Culp WC, JrVillamaria FJ, et al. Developing a checklist: consensus via a modified Delphi technique. J Cardiothorac Vasc Anesth 2016; 30: 855\u2013858."
                    },
                    {
                        "ref-fulltext": "Copeland C, Fisher J, Teodorczuk A. Development of an international undergraduate curriculum for delirium using a modified Delphi process. Age Ageing 2018; 47: 131\u2013137.",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Development of an international undergraduate curriculum for delirium using a modified Delphi process"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr2-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85040557307",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "47"},
                                "pagerange": {
                                    "@first": "131",
                                    "@last": "137"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Copeland",
                                    "ce:indexed-name": "Copeland C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Fisher",
                                    "ce:indexed-name": "Fisher J."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Teodorczuk",
                                    "ce:indexed-name": "Teodorczuk A."
                                }
                            ]},
                            "ref-sourcetitle": "Age Ageing"
                        },
                        "ce:source-text": "Copeland C, Fisher J, Teodorczuk A. Development of an international undergraduate curriculum for delirium using a modified Delphi process. Age Ageing 2018; 47: 131\u2013137."
                    },
                    {
                        "ref-fulltext": "Powell C. The Delphi technique: myths and realities. J Adv Nurs 2003; 41: 376\u2013382.",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2003"},
                            "ref-title": {"ref-titletext": "The Delphi technique: myths and realities"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr3-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "0037315572",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "41"},
                                "pagerange": {
                                    "@first": "376",
                                    "@last": "382"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "C.",
                                "@_fa": "true",
                                "ce:surname": "Powell",
                                "ce:indexed-name": "Powell C."
                            }]},
                            "ref-sourcetitle": "J Adv Nurs"
                        },
                        "ce:source-text": "Powell C. The Delphi technique: myths and realities. J Adv Nurs 2003; 41: 376\u2013382."
                    },
                    {
                        "ref-fulltext": "Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett\u2019s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012; 143: 336\u2013346.",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-title": {"ref-titletext": "Consensus statements for management of Barrett\u2019s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr4-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84864192459",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "143"},
                                "pagerange": {
                                    "@first": "336",
                                    "@last": "346"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Bennett",
                                        "ce:indexed-name": "Bennett C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Vakil",
                                        "ce:indexed-name": "Vakil N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Bergman",
                                        "ce:indexed-name": "Bergman J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Gastroenterology"
                        },
                        "ce:source-text": "Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett\u2019s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012; 143: 336\u2013346."
                    },
                    {
                        "ref-fulltext": "Wood L, Black P, Heng D, et al. Using the Dephi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. J Oncology Practice 2013; 9: 262\u2013267.",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Using the Dephi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr5-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84892575819",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "9"},
                                "pagerange": {
                                    "@first": "262",
                                    "@last": "267"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Wood",
                                        "ce:indexed-name": "Wood L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Black",
                                        "ce:indexed-name": "Black P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Heng",
                                        "ce:indexed-name": "Heng D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Oncology Practice"
                        },
                        "ce:source-text": "Wood L, Black P, Heng D, et al. Using the Dephi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. J Oncology Practice 2013; 9: 262\u2013267."
                    },
                    {
                        "ref-fulltext": "Meshkat B, Cowman S, Gethin G, et al. Using an e-Delphi technique in achieving consensus across disciplines for developing best practice in day surgery in Ireland. J Hosp Adm 2014; 3: 1\u20138.",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Using an e-Delphi technique in achieving consensus across disciplines for developing best practice in day surgery in Ireland"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr6-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84974662824",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "3"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "8"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Meshkat",
                                        "ce:indexed-name": "Meshkat B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Cowman",
                                        "ce:indexed-name": "Cowman S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Gethin",
                                        "ce:indexed-name": "Gethin G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Hosp Adm"
                        },
                        "ce:source-text": "Meshkat B, Cowman S, Gethin G, et al. Using an e-Delphi technique in achieving consensus across disciplines for developing best practice in day surgery in Ireland. J Hosp Adm 2014; 3: 1\u20138."
                    },
                    {
                        "ref-fulltext": "Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998; 2: i\u2013iv, 1\u201388.",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "1998"},
                            "ref-title": {"ref-titletext": "Consensus development methods, and their use in clinical guideline development"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr7-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "0002239144",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "2"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "88"
                                }
                            },
                            "ref-text": "i\u2013iv",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Murphy",
                                        "ce:indexed-name": "Murphy M.K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Black",
                                        "ce:indexed-name": "Black N.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Lamping",
                                        "ce:indexed-name": "Lamping D.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Health Technol Assess"
                        },
                        "ce:source-text": "Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998; 2: i\u2013iv, 1\u201388."
                    },
                    {
                        "ref-fulltext": "Butterwick DJ, Paskevich DM, Lagumen NG, et al. Development of content-valid technical skill assessment instruments for athletic taping skills. J Allied Health 2006; 35: 147\u2013155.",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2006"},
                            "ref-title": {"ref-titletext": "Development of content-valid technical skill assessment instruments for athletic taping skills"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr8-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "33749347033",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "35"},
                                "pagerange": {
                                    "@first": "147",
                                    "@last": "155"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Butterwick",
                                        "ce:indexed-name": "Butterwick D.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Paskevich",
                                        "ce:indexed-name": "Paskevich D.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Lagumen",
                                        "ce:indexed-name": "Lagumen N.G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Allied Health"
                        },
                        "ce:source-text": "Butterwick DJ, Paskevich DM, Lagumen NG, et al. Development of content-valid technical skill assessment instruments for athletic taping skills. J Allied Health 2006; 35: 147\u2013155."
                    },
                    {
                        "ref-fulltext": "Graefe A, Armstrong JS. Comparing face-to-face meetings, nominal groups, Delphi and prediction markets on an estimation task. Int J Forecasting 2016; 27: 183\u2013195.",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Comparing face-to-face meetings, nominal groups, Delphi and prediction markets on an estimation task"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr9-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "78149501001",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "27"},
                                "pagerange": {
                                    "@first": "183",
                                    "@last": "195"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Graefe",
                                    "ce:indexed-name": "Graefe A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Armstrong",
                                    "ce:indexed-name": "Armstrong J.S."
                                }
                            ]},
                            "ref-sourcetitle": "Int J Forecasting"
                        },
                        "ce:source-text": "Graefe A, Armstrong JS. Comparing face-to-face meetings, nominal groups, Delphi and prediction markets on an estimation task. Int J Forecasting 2016; 27: 183\u2013195."
                    },
                    {
                        "ref-fulltext": "Gustafson DH, Shukla RK, Delbecq A, et al. A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, Delphi groups, and nominal groups. Organ Behav Hum Perf 1973; 9: 280\u2013291.",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "1973"},
                            "ref-title": {"ref-titletext": "A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, Delphi groups, and nominal groups"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr10-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "10644249171",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "9"},
                                "pagerange": {
                                    "@first": "280",
                                    "@last": "291"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Gustafson",
                                        "ce:indexed-name": "Gustafson D.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Shukla",
                                        "ce:indexed-name": "Shukla R.K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Delbecq",
                                        "ce:indexed-name": "Delbecq A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Organ Behav Hum Perf"
                        },
                        "ce:source-text": "Gustafson DH, Shukla RK, Delbecq A, et al. A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, Delphi groups, and nominal groups. Organ Behav Hum Perf 1973; 9: 280\u2013291."
                    },
                    {
                        "ref-fulltext": "Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 167: 948\u2013951; discussion 952.",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2002"},
                            "ref-title": {"ref-titletext": "Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr11-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "0009829895",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "167"},
                                "pagerange": {
                                    "@first": "948",
                                    "@last": "951"
                                }
                            },
                            "ref-text": "discussion 952",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Huggins",
                                    "ce:indexed-name": "Huggins C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "C.V.",
                                    "@_fa": "true",
                                    "ce:surname": "Hodges",
                                    "ce:indexed-name": "Hodges C.V."
                                }
                            ]},
                            "ref-sourcetitle": "J Urol"
                        },
                        "ce:source-text": "Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 167: 948\u2013951; discussion 952."
                    },
                    {
                        "ref-fulltext": "Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion [published correction appears in Nat Clin Pract Urol2009 Mar;6(3):173]. Nat Clin Pract Urol 2009; 6: 76\u201385.",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-title": {"ref-titletext": "Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion [published correction appears in Nat Clin Pract Urol2009 Mar;6(3):173]"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr12-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "60149089419",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "6"},
                                "pagerange": {
                                    "@first": "76",
                                    "@last": "85"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "W.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Harris",
                                        "ce:indexed-name": "Harris W.P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Mostaghel",
                                        "ce:indexed-name": "Mostaghel E.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Nelson",
                                        "ce:indexed-name": "Nelson P.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Clin Pract Urol"
                        },
                        "ce:source-text": "Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion [published correction appears in Nat Clin Pract Urol2009 Mar;6(3):173]. Nat Clin Pract Urol 2009; 6: 76\u201385."
                    },
                    {
                        "ref-fulltext": "Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737\u2013746.",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Chemohormonal therapy in metastatic hormone-sensitive prostate cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr13-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84939864061",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "373"},
                                "pagerange": {
                                    "@first": "737",
                                    "@last": "746"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Sweeney",
                                        "ce:indexed-name": "Sweeney C.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Chen",
                                        "ce:indexed-name": "Chen Y.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Carducci",
                                        "ce:indexed-name": "Carducci M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737\u2013746."
                    },
                    {
                        "ref-fulltext": "James ND, Sydes MR, Clarke NW, et al. STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163\u20131177.",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr14-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84961215473",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "387"},
                                "pagerange": {
                                    "@first": "1163",
                                    "@last": "1177"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.D.",
                                        "@_fa": "true",
                                        "ce:surname": "James",
                                        "ce:indexed-name": "James N.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Sydes",
                                        "ce:indexed-name": "Sydes M.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Clarke",
                                        "ce:indexed-name": "Clarke N.W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "James ND, Sydes MR, Clarke NW, et al. STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163\u20131177."
                    },
                    {
                        "ref-fulltext": "Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017; 377: 352\u2013360.",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr15-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85020848493",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "377"},
                                "pagerange": {
                                    "@first": "352",
                                    "@last": "360"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Fizazi",
                                        "ce:indexed-name": "Fizazi K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Tran",
                                        "ce:indexed-name": "Tran N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Fein",
                                        "ce:indexed-name": "Fein L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017; 377: 352\u2013360."
                    },
                    {
                        "ref-fulltext": "James ND, de Bono JS, Spears MR, et al. STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017; 377: 338\u2013351.",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr16-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85020467336",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "377"},
                                "pagerange": {
                                    "@first": "338",
                                    "@last": "351"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.D.",
                                        "@_fa": "true",
                                        "ce:surname": "James",
                                        "ce:indexed-name": "James N.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.S.",
                                        "@_fa": "true",
                                        "ce:surname": "de Bono",
                                        "ce:indexed-name": "de Bono J.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Spears",
                                        "ce:indexed-name": "Spears M.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "James ND, de Bono JS, Spears MR, et al. STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017; 377: 338\u2013351."
                    },
                    {
                        "ref-fulltext": "Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUGAFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 149\u2013158.",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUGAFU 15): a randomised, open-label, phase 3 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr17-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84873095322",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "14"},
                                "pagerange": {
                                    "@first": "149",
                                    "@last": "158"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Gravis",
                                        "ce:indexed-name": "Gravis G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Fizazi",
                                        "ce:indexed-name": "Fizazi K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Joly",
                                        "ce:indexed-name": "Joly F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUGAFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 149\u2013158."
                    },
                    {
                        "ref-fulltext": "Egevad L, Granfors T, Karlberg L, et al. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002; 89: 538\u2013542.",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2002"},
                            "ref-title": {"ref-titletext": "Prognostic value of the Gleason score in prostate cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr18-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "0036343847",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "89"},
                                "pagerange": {
                                    "@first": "538",
                                    "@last": "542"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Egevad",
                                        "ce:indexed-name": "Egevad L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Granfors",
                                        "ce:indexed-name": "Granfors T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Karlberg",
                                        "ce:indexed-name": "Karlberg L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "BJU Int"
                        },
                        "ce:source-text": "Egevad L, Granfors T, Karlberg L, et al. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002; 89: 538\u2013542."
                    },
                    {
                        "ref-fulltext": "James ND, Sydes MR, Clarke NW, et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multiarm, multistage randomized controlled trial. BJU Int 2009; 103: 464\u2013469.",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-title": {"ref-titletext": "Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multiarm, multistage randomized controlled trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr19-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "59249100332",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "103"},
                                "pagerange": {
                                    "@first": "464",
                                    "@last": "469"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.D.",
                                        "@_fa": "true",
                                        "ce:surname": "James",
                                        "ce:indexed-name": "James N.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Sydes",
                                        "ce:indexed-name": "Sydes M.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Clarke",
                                        "ce:indexed-name": "Clarke N.W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "BJU Int"
                        },
                        "ce:source-text": "James ND, Sydes MR, Clarke NW, et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multiarm, multistage randomized controlled trial. BJU Int 2009; 103: 464\u2013469."
                    },
                    {
                        "ref-fulltext": "Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018; 36: 1080\u20131087.",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr20-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85044992412",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "36"},
                                "pagerange": {
                                    "@first": "1080",
                                    "@last": "1087"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Kyriakopoulos",
                                        "ce:indexed-name": "Kyriakopoulos C.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Chen",
                                        "ce:indexed-name": "Chen Y.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Carducci",
                                        "ce:indexed-name": "Carducci M.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018; 36: 1080\u20131087."
                    },
                    {
                        "ref-fulltext": "Chiong E, Murphy DG, Akaza H, et al. Management of patients with advanced prostate cancer in the Asia Pacific region: \u2018real-world\u2019 consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. BJU Int 2019; 123: 22\u201334.",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr21-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85052790498",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "123"},
                                "pagerange": {
                                    "@first": "22",
                                    "@last": "34"
                                }
                            },
                            "ref-text": "BJU Int",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Chiong",
                                        "ce:indexed-name": "Chiong E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Murphy",
                                        "ce:indexed-name": "Murphy D.G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Akaza",
                                        "ce:indexed-name": "Akaza H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Management of patients with advanced prostate cancer in the Asia Pacific region: \u2018real-world\u2019 consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017"
                        },
                        "ce:source-text": "Chiong E, Murphy DG, Akaza H, et al. Management of patients with advanced prostate cancer in the Asia Pacific region: \u2018real-world\u2019 consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. BJU Int 2019; 123: 22\u201334."
                    },
                    {
                        "ref-fulltext": "Gravis G, Boher JM, Joly F, et al. GETUG. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur Urol 2016; 70: 256\u2013262.",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr22-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84947609787",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "70"},
                                "pagerange": {
                                    "@first": "256",
                                    "@last": "262"
                                }
                            },
                            "ref-text": "GETUG",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Gravis",
                                        "ce:indexed-name": "Gravis G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Boher",
                                        "ce:indexed-name": "Boher J.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Joly",
                                        "ce:indexed-name": "Joly F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur Urol"
                        },
                        "ce:source-text": "Gravis G, Boher JM, Joly F, et al. GETUG. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur Urol 2016; 70: 256\u2013262."
                    },
                    {
                        "ref-fulltext": "Feyerabend S, Saad F, Li T, et al. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis. Eur J Cancer 2018; 103: 78\u201387.",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr23-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85053046048",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "103"},
                                "pagerange": {
                                    "@first": "78",
                                    "@last": "87"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Feyerabend",
                                        "ce:indexed-name": "Feyerabend S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Saad",
                                        "ce:indexed-name": "Saad F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur J Cancer"
                        },
                        "ce:source-text": "Feyerabend S, Saad F, Li T, et al. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis. Eur J Cancer 2018; 103: 78\u201387."
                    },
                    {
                        "ref-fulltext": "Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial [published correction appears in Ann Oncol. 2020 Mar;31(3):442]. Ann Oncol. 2019; 30: 1992\u20132003.",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial [published correction appears in Ann Oncol. 2020 Mar;31(3):442]"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr24-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85074637334",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "30"},
                                "pagerange": {
                                    "@first": "1992",
                                    "@last": "2003"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Clarke",
                                        "ce:indexed-name": "Clarke N.W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ali",
                                        "ce:indexed-name": "Ali A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Ingleby",
                                        "ce:indexed-name": "Ingleby F.C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial [published correction appears in Ann Oncol. 2020 Mar;31(3):442]. Ann Oncol. 2019; 30: 1992\u20132003."
                    },
                    {
                        "ref-fulltext": "Ritch C, Cookson M. Recent trends in the management of advanced prostate cancer. F1000Res 2018; 7: F1000 Faculty Rev-1513.",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Recent trends in the management of advanced prostate cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr25-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85055074547",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "7"}},
                            "ref-text": "F1000 Faculty Rev-1513",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Ritch",
                                    "ce:indexed-name": "Ritch C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Cookson",
                                    "ce:indexed-name": "Cookson M."
                                }
                            ]},
                            "ref-sourcetitle": "F1000Res"
                        },
                        "ce:source-text": "Ritch C, Cookson M. Recent trends in the management of advanced prostate cancer. F1000Res 2018; 7: F1000 Faculty Rev-1513."
                    },
                    {
                        "ref-fulltext": "Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138\u2013148.",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Abiraterone in metastatic prostate cancer without previous chemotherapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr26-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84872078210",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "368"},
                                "pagerange": {
                                    "@first": "138",
                                    "@last": "148"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Ryan",
                                        "ce:indexed-name": "Ryan C.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Smith",
                                        "ce:indexed-name": "Smith M.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.S.",
                                        "@_fa": "true",
                                        "ce:surname": "de Bono",
                                        "ce:indexed-name": "de Bono J.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138\u2013148."
                    },
                    {
                        "ref-fulltext": "Ye D, Huang Y, Zhou F, et al. A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia. Asian J Urol 2017; 4: 75\u201385.",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr27-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85027752851",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "4"},
                                "pagerange": {
                                    "@first": "75",
                                    "@last": "85"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Ye",
                                        "ce:indexed-name": "Ye D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Huang",
                                        "ce:indexed-name": "Huang Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhou",
                                        "ce:indexed-name": "Zhou F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Asian J Urol"
                        },
                        "ce:source-text": "Ye D, Huang Y, Zhou F, et al. A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia. Asian J Urol 2017; 4: 75\u201385."
                    },
                    {
                        "ref-fulltext": "Goodman OB, JrFraig TW, Molina A, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2014; 17: 34e9.",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr28-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84894085480",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "17"}},
                            "ref-text": "34e9",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "O.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Goodman",
                                        "ce:suffix": "Jr.",
                                        "ce:indexed-name": "Goodman O.B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Fraig",
                                        "ce:indexed-name": "Fraig T.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Molina",
                                        "ce:indexed-name": "Molina A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Prostate Cancer Prostatic Dis"
                        },
                        "ce:source-text": "Goodman OB, JrFraig TW, Molina A, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2014; 17: 34e9."
                    },
                    {
                        "ref-fulltext": "Lojanapiwat B, Pripatnanont C, Choonhaklai V, et al. Management of metastatic castration-resistant prostate cancer: insights from urology experts in Thailand. Prostate Int 2017; 5: 1\u20137.",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Management of metastatic castration-resistant prostate cancer: insights from urology experts in Thailand"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr29-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85012939668",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "5"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "7"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Lojanapiwat",
                                        "ce:indexed-name": "Lojanapiwat B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Pripatnanont",
                                        "ce:indexed-name": "Pripatnanont C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Choonhaklai",
                                        "ce:indexed-name": "Choonhaklai V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Prostate Int"
                        },
                        "ce:source-text": "Lojanapiwat B, Pripatnanont C, Choonhaklai V, et al. Management of metastatic castration-resistant prostate cancer: insights from urology experts in Thailand. Prostate Int 2017; 5: 1\u20137."
                    },
                    {
                        "ref-fulltext": "Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018; 73: 178\u2013211.",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr30-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85021207004",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "73"},
                                "pagerange": {
                                    "@first": "178",
                                    "@last": "211"
                                }
                            },
                            "ref-text": "Eur Urol",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Gillessen",
                                        "ce:indexed-name": "Gillessen S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Attard",
                                        "ce:indexed-name": "Attard G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Beer",
                                        "ce:indexed-name": "Beer T.M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017"
                        },
                        "ce:source-text": "Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018; 73: 178\u2013211."
                    },
                    {
                        "ref-fulltext": "McNamara MA, George DJ, Ramaswamy K, et al. Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide. J Clin Oncol 2019; 37: (7_Suppl.): 212\u2013212.",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr31-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85069270636",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "37"},
                                "pagerange": {"@first": "212"}
                            },
                            "ref-text": "(7_Sul",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.A.",
                                        "@_fa": "true",
                                        "ce:surname": "McNamara",
                                        "ce:indexed-name": "McNamara M.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.J.",
                                        "@_fa": "true",
                                        "ce:surname": "George",
                                        "ce:indexed-name": "George D.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Ramaswamy",
                                        "ce:indexed-name": "Ramaswamy K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "McNamara MA, George DJ, Ramaswamy K, et al. Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide. J Clin Oncol 2019; 37: (7_Suppl.): 212\u2013212."
                    },
                    {
                        "ref-fulltext": "Thiery-Vuillemin A, Poulsen MH, Dourthe L-M, et al. Six-month patient-reported outcome results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate + prednisone or enzalutamide. AQUARIUS. Presented at the ASCO Annual Meeting, Chicago, Ill, 1\u20135 June 2018, ASCO.",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr32-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85101590252",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Presented at the ASCO Annual Meeting, Chicago, Ill, 1\u20135, June, ASCO",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Thiery-Vuillemin",
                                        "ce:indexed-name": "Thiery-Vuillemin A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Poulsen",
                                        "ce:indexed-name": "Poulsen M.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.-M.",
                                        "@_fa": "true",
                                        "ce:surname": "Dourthe",
                                        "ce:indexed-name": "Dourthe L.-M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Six-month patient-reported outcome results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate + prednisone or enzalutamide. AQUARIUS"
                        },
                        "ce:source-text": "Thiery-Vuillemin A, Poulsen MH, Dourthe L-M, et al. Six-month patient-reported outcome results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate + prednisone or enzalutamide. AQUARIUS. Presented at the ASCO Annual Meeting, Chicago, Ill, 1\u20135 June 2018, ASCO."
                    },
                    {
                        "ref-fulltext": "Shore ND, Saltzstein DR, Sieber PR, et al. Real-world study of enzalutamide and abiraterone acetate (with prednisone) tolerability (REAAcT): results. Presented at the Genitourinary Cancers Symposium, San Francisco, CA, 8\u201310 February 2018, ASCO GU.",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr33-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85101538604",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "San Francisco, CA, 8\u201310, February, Presented at the Genitourinary Cancers Symposium, ASCO GU",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Shore",
                                        "ce:indexed-name": "Shore N.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Saltzstein",
                                        "ce:indexed-name": "Saltzstein D.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Sieber",
                                        "ce:indexed-name": "Sieber P.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Real-world study of enzalutamide and abiraterone acetate (with prednisone) tolerability (REAAcT): results"
                        },
                        "ce:source-text": "Shore ND, Saltzstein DR, Sieber PR, et al. Real-world study of enzalutamide and abiraterone acetate (with prednisone) tolerability (REAAcT): results. Presented at the Genitourinary Cancers Symposium, San Francisco, CA, 8\u201310 February 2018, ASCO GU."
                    },
                    {
                        "ref-fulltext": "James ND, de Bono JS, Spears MR, et al. Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476). Ann Oncol 28(Suppl. 5): mdx440.027.",
                        "@id": "34",
                        "ref-info": {
                            "ref-title": {"ref-titletext": "Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr34-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85101508919",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "440"},
                                "pagerange": {"@first": "027"}
                            },
                            "ref-text": "(,): mdx",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.D.",
                                        "@_fa": "true",
                                        "ce:surname": "James",
                                        "ce:indexed-name": "James N.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.S.",
                                        "@_fa": "true",
                                        "ce:surname": "de Bono",
                                        "ce:indexed-name": "de Bono J.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Spears",
                                        "ce:indexed-name": "Spears M.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "James ND, de Bono JS, Spears MR, et al. Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476). Ann Oncol 28(Suppl. 5): mdx440.027."
                    },
                    {
                        "ref-fulltext": "Ryan CJ, Crawford ED, Shore ND, et al. The IMAAGEN study: effect of abiraterone acetate and prednisone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer. J Urol 2018; 200: 344\u2013352.",
                        "@id": "35",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "The IMAAGEN study: effect of abiraterone acetate and prednisone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr35-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85048726451",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "200"},
                                "pagerange": {
                                    "@first": "344",
                                    "@last": "352"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Ryan",
                                        "ce:indexed-name": "Ryan C.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Crawford",
                                        "ce:indexed-name": "Crawford E.D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Shore",
                                        "ce:indexed-name": "Shore N.D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Urol"
                        },
                        "ce:source-text": "Ryan CJ, Crawford ED, Shore ND, et al. The IMAAGEN study: effect of abiraterone acetate and prednisone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer. J Urol 2018; 200: 344\u2013352."
                    },
                    {
                        "ref-fulltext": "Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019; 17: 479\u2013505.",
                        "@id": "36",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr36-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85066270032",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "17"},
                                "pagerange": {
                                    "@first": "479",
                                    "@last": "505"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Mohler",
                                        "ce:indexed-name": "Mohler J.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Antonarakis",
                                        "ce:indexed-name": "Antonarakis E.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Armstrong",
                                        "ce:indexed-name": "Armstrong A.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Natl Compr Canc Netw"
                        },
                        "ce:source-text": "Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019; 17: 479\u2013505."
                    },
                    {
                        "ref-fulltext": "Malangone-Monaco E, Foley K, Varker H, et al. Prescribing patterns of oral antineoplastic therapies observed in the treatment of patients with advanced prostate cancer between 2012 and 2014: Results of an oncology EMR analysis. Clin Ther 2016; 38: 1817\u20131824.",
                        "@id": "37",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Prescribing patterns of oral antineoplastic therapies observed in the treatment of patients with advanced prostate cancer between 2012 and 2014: Results of an oncology EMR analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr37-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84982243105",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "38"},
                                "pagerange": {
                                    "@first": "1817",
                                    "@last": "1824"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Malangone-Monaco",
                                        "ce:indexed-name": "Malangone-Monaco E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Foley",
                                        "ce:indexed-name": "Foley K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Varker",
                                        "ce:indexed-name": "Varker H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Ther"
                        },
                        "ce:source-text": "Malangone-Monaco E, Foley K, Varker H, et al. Prescribing patterns of oral antineoplastic therapies observed in the treatment of patients with advanced prostate cancer between 2012 and 2014: Results of an oncology EMR analysis. Clin Ther 2016; 38: 1817\u20131824."
                    },
                    {
                        "ref-fulltext": "Stuyckens K, Saad F, Xu XS, et al. Population pharmacokinetic analysis of abiraterone in chemotherapy- naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet 2014; 53: 1149\u20131160.",
                        "@id": "38",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Population pharmacokinetic analysis of abiraterone in chemotherapy- naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr38-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84920953021",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "53"},
                                "pagerange": {
                                    "@first": "1149",
                                    "@last": "1160"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Stuyckens",
                                        "ce:indexed-name": "Stuyckens K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Saad",
                                        "ce:indexed-name": "Saad F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Xu",
                                        "ce:indexed-name": "Xu X.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Pharmacokinet"
                        },
                        "ce:source-text": "Stuyckens K, Saad F, Xu XS, et al. Population pharmacokinetic analysis of abiraterone in chemotherapy- naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet 2014; 53: 1149\u20131160."
                    },
                    {
                        "ref-fulltext": "Center for Drug Evaluation and Research. Application number: 202379Orig1s000. Clinical pharmacology and biopharmaceutics review(s), https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379orig1s000clinpharmr.pdf (2011, accessed 10 February 2020)",
                        "@id": "39",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379orig1s000clinpharmr.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr39-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85101499212",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Alication number: 202379Orig1s000. Clinical pharmacology and biopharmaceutics review(s), (2011, accessed 10 February 2020",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Center for Drug Evaluation and Research",
                                "ce:indexed-name": "Center for Drug Evaluation and Research"
                            }}
                        },
                        "ce:source-text": "Center for Drug Evaluation and Research. Application number: 202379Orig1s000. Clinical pharmacology and biopharmaceutics review(s), https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379orig1s000clinpharmr.pdf (2011, accessed 10 February 2020)"
                    },
                    {
                        "ref-fulltext": "Szmulewitz RZ, Peer CJ, Ibraheem A, et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol 2018; 36: 1389\u20131395.",
                        "@id": "40",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr40-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85046945419",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "36"},
                                "pagerange": {
                                    "@first": "1389",
                                    "@last": "1395"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Szmulewitz",
                                        "ce:indexed-name": "Szmulewitz R.Z."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Peer",
                                        "ce:indexed-name": "Peer C.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ibraheem",
                                        "ce:indexed-name": "Ibraheem A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Szmulewitz RZ, Peer CJ, Ibraheem A, et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol 2018; 36: 1389\u20131395."
                    },
                    {
                        "ref-fulltext": "Kolesar JM, Liu GX. Low-fat abiraterone food effect is of little consequence. J Clin Oncol 2018; 36: 1385\u20131387.",
                        "@id": "41",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Low-fat abiraterone food effect is of little consequence"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr41-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85046940954",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "36"},
                                "pagerange": {
                                    "@first": "1385",
                                    "@last": "1387"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.M.",
                                    "@_fa": "true",
                                    "ce:surname": "Kolesar",
                                    "ce:indexed-name": "Kolesar J.M."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "G.X.",
                                    "@_fa": "true",
                                    "ce:surname": "Liu",
                                    "ce:indexed-name": "Liu G.X."
                                }
                            ]},
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Kolesar JM, Liu GX. Low-fat abiraterone food effect is of little consequence. J Clin Oncol 2018; 36: 1385\u20131387."
                    },
                    {
                        "ref-fulltext": "Nadiminty N, Tummala R, Liu C, et al. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther 2013; 12: 1629\u20131637.",
                        "@id": "42",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr42-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84882274167",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "12"},
                                "pagerange": {
                                    "@first": "1629",
                                    "@last": "1637"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Nadiminty",
                                        "ce:indexed-name": "Nadiminty N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Tummala",
                                        "ce:indexed-name": "Tummala R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Mol Cancer Ther"
                        },
                        "ce:source-text": "Nadiminty N, Tummala R, Liu C, et al. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther 2013; 12: 1629\u20131637."
                    },
                    {
                        "ref-fulltext": "Sepe P, Verzoni E, Miodini P, et al. Could circulating tumor cells and ARV7 detection improve clinical decisions in metastatic castration-resistant prostate cancer? The Istituto Nazionale dei Tumori (INT) Experience. Cancers 2019; 11: E980.",
                        "@id": "43",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Could circulating tumor cells and ARV7 detection improve clinical decisions in metastatic castration-resistant prostate cancer? The Istituto Nazionale dei Tumori (INT) Experience"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr43-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85071368842",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "11"},
                                "pagerange": {"@first": "E980"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Sepe",
                                        "ce:indexed-name": "Sepe P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Verzoni",
                                        "ce:indexed-name": "Verzoni E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Miodini",
                                        "ce:indexed-name": "Miodini P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancers"
                        },
                        "ce:source-text": "Sepe P, Verzoni E, Miodini P, et al. Could circulating tumor cells and ARV7 detection improve clinical decisions in metastatic castration-resistant prostate cancer? The Istituto Nazionale dei Tumori (INT) Experience. Cancers 2019; 11: E980."
                    },
                    {
                        "ref-fulltext": "Armstrong AJ, Halabi S, Luo J, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J Clin Oncol 2019; 37: 1120\u20131129.",
                        "@id": "44",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr44-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85065325919",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "37"},
                                "pagerange": {
                                    "@first": "1120",
                                    "@last": "1129"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Armstrong",
                                        "ce:indexed-name": "Armstrong A.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Halabi",
                                        "ce:indexed-name": "Halabi S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Luo",
                                        "ce:indexed-name": "Luo J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Armstrong AJ, Halabi S, Luo J, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J Clin Oncol 2019; 37: 1120\u20131129."
                    },
                    {
                        "ref-fulltext": "Bastos DA, Antonarakis ES. AR-V7 and treatment selection in advanced prostate cancer: are we there yet? Precis Cancer Med 2018; 1: 13.",
                        "@id": "45",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "AR-V7 and treatment selection in advanced prostate cancer: are we there yet?"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr45-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85081324377",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "1"},
                                "pagerange": {"@first": "13"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "D.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Bastos",
                                    "ce:indexed-name": "Bastos D.A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "E.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Antonarakis",
                                    "ce:indexed-name": "Antonarakis E.S."
                                }
                            ]},
                            "ref-sourcetitle": "Precis Cancer Med"
                        },
                        "ce:source-text": "Bastos DA, Antonarakis ES. AR-V7 and treatment selection in advanced prostate cancer: are we there yet? Precis Cancer Med 2018; 1: 13."
                    },
                    {
                        "ref-fulltext": "Castellan P, Marchioni M, Castellucci R, et al. Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations. Ther Clin Risk Manag 2018; 14: 2341\u20132347.",
                        "@id": "46",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr46-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85058474573",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "14"},
                                "pagerange": {
                                    "@first": "2341",
                                    "@last": "2347"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Castellan",
                                        "ce:indexed-name": "Castellan P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Marchioni",
                                        "ce:indexed-name": "Marchioni M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Castellucci",
                                        "ce:indexed-name": "Castellucci R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ther Clin Risk Manag"
                        },
                        "ce:source-text": "Castellan P, Marchioni M, Castellucci R, et al. Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations. Ther Clin Risk Manag 2018; 14: 2341\u20132347."
                    },
                    {
                        "ref-fulltext": "Hahn AW, Higano CS, Taplin M, et al. Metastatic castration-sensitive prostate cancer: optimizing patient selection and treatment. Am Soc Clin Oncol Educ Book 2018; 38: 363\u2013371.",
                        "@id": "47",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Metastatic castration-sensitive prostate cancer: optimizing patient selection and treatment"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr47-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85057293564",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "38"},
                                "pagerange": {
                                    "@first": "363",
                                    "@last": "371"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Hahn",
                                        "ce:indexed-name": "Hahn A.W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Higano",
                                        "ce:indexed-name": "Higano C.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Taplin",
                                        "ce:indexed-name": "Taplin M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Am Soc Clin Oncol Educ Book"
                        },
                        "ce:source-text": "Hahn AW, Higano CS, Taplin M, et al. Metastatic castration-sensitive prostate cancer: optimizing patient selection and treatment. Am Soc Clin Oncol Educ Book 2018; 38: 363\u2013371."
                    },
                    {
                        "ref-fulltext": "Wang C, Hu C, Gao D, et al. Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers. Cancer Chemother Pharmacol 2019; 83: 509\u2013517.",
                        "@id": "48",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr48-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85058154780",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "83"},
                                "pagerange": {
                                    "@first": "509",
                                    "@last": "517"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Hu",
                                        "ce:indexed-name": "Hu C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Gao",
                                        "ce:indexed-name": "Gao D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Chemother Pharmacol"
                        },
                        "ce:source-text": "Wang C, Hu C, Gao D, et al. Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers. Cancer Chemother Pharmacol 2019; 83: 509\u2013517."
                    },
                    {
                        "ref-fulltext": "Aggarwal R: Abiraterone or docetaxel plus androgen deprivation in hormone-sensitive prostate cancer: more questions than answers. Eur Urol 2018; 73: 845\u2013846.",
                        "@id": "49",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr49-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85033411497",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "73"},
                                "pagerange": {
                                    "@first": "845",
                                    "@last": "846"
                                }
                            },
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Aggarwal R: Abiraterone or docetaxel plus androgen deprivation in hormone-sensitive prostate cancer: more questions than answers",
                                "ce:indexed-name": "Aggarwal R: Abiraterone or docetaxel plus androgen deprivation in hormone-sensitive prostate cancer: more questions than answers"
                            }},
                            "ref-sourcetitle": "Eur Urol"
                        },
                        "ce:source-text": "Aggarwal R: Abiraterone or docetaxel plus androgen deprivation in hormone-sensitive prostate cancer: more questions than answers. Eur Urol 2018; 73: 845\u2013846."
                    },
                    {
                        "ref-fulltext": "Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 2018; 29: 1235\u20131248.",
                        "@id": "50",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr50-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85045001847",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "29"},
                                "pagerange": {
                                    "@first": "1235",
                                    "@last": "1248"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Sydes",
                                        "ce:indexed-name": "Sydes M.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Spears",
                                        "ce:indexed-name": "Spears M.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Mason",
                                        "ce:indexed-name": "Mason M.D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 2018; 29: 1235\u20131248."
                    },
                    {
                        "ref-fulltext": "Wallis CJD, Klaassen Z, Bhindi B, et al. Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naïve prostate cancer: a systematic review and network meta-analysis. Eur Urol 2018; 73: 834\u2013844.",
                        "@id": "51",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naïve prostate cancer: a systematic review and network meta-analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr51-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85031322705",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "73"},
                                "pagerange": {
                                    "@first": "834",
                                    "@last": "844"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.J.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Wallis",
                                        "ce:indexed-name": "Wallis C.J.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Klaassen",
                                        "ce:indexed-name": "Klaassen Z."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Bhindi",
                                        "ce:indexed-name": "Bhindi B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur Urol"
                        },
                        "ce:source-text": "Wallis CJD, Klaassen Z, Bhindi B, et al. Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naïve prostate cancer: a systematic review and network meta-analysis. Eur Urol 2018; 73: 834\u2013844."
                    },
                    {
                        "ref-fulltext": "Vale CL, Fisher DJ, White IR, et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol 2018; 29: 1249\u20131257.",
                        "@id": "52",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr52-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85045121224",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "29"},
                                "pagerange": {
                                    "@first": "1249",
                                    "@last": "1257"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Vale",
                                        "ce:indexed-name": "Vale C.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Fisher",
                                        "ce:indexed-name": "Fisher D.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.R.",
                                        "@_fa": "true",
                                        "ce:surname": "White",
                                        "ce:indexed-name": "White I.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Vale CL, Fisher DJ, White IR, et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol 2018; 29: 1249\u20131257."
                    },
                    {
                        "ref-fulltext": "Xu L, Pachynski RK. Contemporary management of the newly diagnosed prostate cancer patient with metastatic disease at presentation. Curr Urol Rep 2018; 19: 79.",
                        "@id": "53",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Contemporary management of the newly diagnosed prostate cancer patient with metastatic disease at presentation"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr53-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85051635971",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "19"},
                                "pagerange": {"@first": "79"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "L.",
                                    "@_fa": "true",
                                    "ce:surname": "Xu",
                                    "ce:indexed-name": "Xu L."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "R.K.",
                                    "@_fa": "true",
                                    "ce:surname": "Pachynski",
                                    "ce:indexed-name": "Pachynski R.K."
                                }
                            ]},
                            "ref-sourcetitle": "Curr Urol Rep"
                        },
                        "ce:source-text": "Xu L, Pachynski RK. Contemporary management of the newly diagnosed prostate cancer patient with metastatic disease at presentation. Curr Urol Rep 2018; 19: 79."
                    },
                    {
                        "ref-fulltext": "Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019; 381: 121\u2013131.",
                        "@id": "54",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Enzalutamide with standard first-line therapy in metastatic prostate cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr54-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85068561926",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "381"},
                                "pagerange": {
                                    "@first": "121",
                                    "@last": "131"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "I.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Davis",
                                        "ce:indexed-name": "Davis I.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Martin",
                                        "ce:indexed-name": "Martin A.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Stockler",
                                        "ce:indexed-name": "Stockler M.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019; 381: 121\u2013131."
                    },
                    {
                        "ref-fulltext": "Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019; 381: 13\u201324.",
                        "@id": "55",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Apalutamide for metastatic, castration-sensitive prostate cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr55-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85068436470",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "381"},
                                "pagerange": {
                                    "@first": "13",
                                    "@last": "24"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Chi",
                                        "ce:indexed-name": "Chi K.N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Agarwal",
                                        "ce:indexed-name": "Agarwal N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Bjartell",
                                        "ce:indexed-name": "Bjartell A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019; 381: 13\u201324."
                    },
                    {
                        "ref-fulltext": "Smith MR, Saad F, Hussain M, et al. ARASENS: a phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol 2018; 36(6_Suppl.): TPS383.",
                        "@id": "56",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "ARASENS: a phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr56-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85074963083",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {"@volume": "36"}},
                            "ref-text": "(6_Sul.): TPS383",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Smith",
                                        "ce:indexed-name": "Smith M.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Saad",
                                        "ce:indexed-name": "Saad F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Hussain",
                                        "ce:indexed-name": "Hussain M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Smith MR, Saad F, Hussain M, et al. ARASENS: a phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol 2018; 36(6_Suppl.): TPS383."
                    },
                    {
                        "ref-fulltext": "Fitzpatrick JM, Bellmunt J, Fizazi K, et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 2014; 50: 1617\u20131627.",
                        "@id": "57",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr57-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84901231924",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "50"},
                                "pagerange": {
                                    "@first": "1617",
                                    "@last": "1627"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Fitzpatrick",
                                        "ce:indexed-name": "Fitzpatrick J.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Bellmunt",
                                        "ce:indexed-name": "Bellmunt J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Fizazi",
                                        "ce:indexed-name": "Fizazi K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur J Cancer"
                        },
                        "ce:source-text": "Fitzpatrick JM, Bellmunt J, Fizazi K, et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 2014; 50: 1617\u20131627."
                    },
                    {
                        "ref-fulltext": "Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983\u2013992.",
                        "@id": "58",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-title": {"ref-titletext": "Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr58-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84866948935",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "13"},
                                "pagerange": {
                                    "@first": "983",
                                    "@last": "992"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Fizazi",
                                        "ce:indexed-name": "Fizazi K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Scher",
                                        "ce:indexed-name": "Scher H.I."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Molina",
                                        "ce:indexed-name": "Molina A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983\u2013992."
                    },
                    {
                        "ref-fulltext": "Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187\u20131197.",
                        "@id": "59",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-title": {"ref-titletext": "Increased survival with enzalutamide in prostate cancer after chemotherapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr59-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84866770294",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "367"},
                                "pagerange": {
                                    "@first": "1187",
                                    "@last": "1197"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Scher",
                                        "ce:indexed-name": "Scher H.I."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Fizazi",
                                        "ce:indexed-name": "Fizazi K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Saad",
                                        "ce:indexed-name": "Saad F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187\u20131197."
                    },
                    {
                        "ref-fulltext": "Noonan KL, North S, Bitting RL, et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013; 24: 1802\u20131807.",
                        "@id": "60",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr60-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84882799782",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "24"},
                                "pagerange": {
                                    "@first": "1802",
                                    "@last": "1807"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Noonan",
                                        "ce:indexed-name": "Noonan K.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "North",
                                        "ce:indexed-name": "North S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Bitting",
                                        "ce:indexed-name": "Bitting R.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Noonan KL, North S, Bitting RL, et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013; 24: 1802\u20131807."
                    },
                    {
                        "ref-fulltext": "Matsubara N, Yamada Y, Tabata KI, et al. Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2018; 16: 142\u2013148.",
                        "@id": "61",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr61-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85031396959",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "16"},
                                "pagerange": {
                                    "@first": "142",
                                    "@last": "148"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Matsubara",
                                        "ce:indexed-name": "Matsubara N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Yamada",
                                        "ce:indexed-name": "Yamada Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Tabata",
                                        "ce:indexed-name": "Tabata K.I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Genitourin Cancer"
                        },
                        "ce:source-text": "Matsubara N, Yamada Y, Tabata KI, et al. Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2018; 16: 142\u2013148."
                    },
                    {
                        "ref-fulltext": "Fenioux C, Louvet C, Charton E, et al. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. BJU Int 2019; 123: 300\u2013306.",
                        "@id": "62",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr62-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85052932718",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "123"},
                                "pagerange": {
                                    "@first": "300",
                                    "@last": "306"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Fenioux",
                                        "ce:indexed-name": "Fenioux C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Louvet",
                                        "ce:indexed-name": "Louvet C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Charton",
                                        "ce:indexed-name": "Charton E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "BJU Int"
                        },
                        "ce:source-text": "Fenioux C, Louvet C, Charton E, et al. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. BJU Int 2019; 123: 300\u2013306."
                    },
                    {
                        "ref-fulltext": "Romero-Laorden N, Lozano R, Jayaram A, et al. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Br J Cancer 2018; 119: 1052\u20131059.",
                        "@id": "63",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr63-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85052559568",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "119"},
                                "pagerange": {
                                    "@first": "1052",
                                    "@last": "1059"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Romero-Laorden",
                                        "ce:indexed-name": "Romero-Laorden N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Lozano",
                                        "ce:indexed-name": "Lozano R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Jayaram",
                                        "ce:indexed-name": "Jayaram A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Br J Cancer"
                        },
                        "ce:source-text": "Romero-Laorden N, Lozano R, Jayaram A, et al. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Br J Cancer 2018; 119: 1052\u20131059."
                    },
                    {
                        "ref-fulltext": "Lorente D, Omlin A, Ferraldeschi R, et al. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer 2014; 111: 2248\u20132253.",
                        "@id": "64",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bibr64-1758835920985464",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84927578069",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "111"},
                                "pagerange": {
                                    "@first": "2248",
                                    "@last": "2253"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Lorente",
                                        "ce:indexed-name": "Lorente D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Omlin",
                                        "ce:indexed-name": "Omlin A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Ferraldeschi",
                                        "ce:indexed-name": "Ferraldeschi R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Br J Cancer"
                        },
                        "ce:source-text": "Lorente D, Omlin A, Ferraldeschi R, et al. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer 2014; 111: 2248\u20132253."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199578",
            "affilname": "Ramathibodi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hyderabad",
            "@id": "60017484",
            "affilname": "Dr. Reddy's Laboratories Ltd. India",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017484",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Kuala Lumpur",
            "@id": "60013665",
            "affilname": "University of Malaya Medical Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013665",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": null,
            "@id": "60103837",
            "affilname": "Hospital Pulau Pinang",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60103837",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Ho Chi Minh City",
            "@id": "60071389",
            "affilname": "Cho Ray Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071389",
            "affiliation-country": "Viet Nam"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60005255",
            "affilname": "Rajavithi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005255",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bandar Sunway",
            "@id": "121444563",
            "affilname": "Sunway Medical Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/121444563",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Ho Chi Minh City",
            "@id": "107981430",
            "affilname": "Ho Chi Minh City Oncology Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/107981430",
            "affiliation-country": "Viet Nam"
        },
        {
            "affiliation-city": "Hanoi",
            "@id": "100787418",
            "affilname": "National Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100787418",
            "affiliation-country": "Viet Nam"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85101563160",
        "dc:description": "Aims: Clinical decision making is challenging in men with metastatic prostate cancer (mPC), as heterogeneity in treatment options and patient characteristics have resulted in multiple scenarios with little or no evidence. The South East Asia Expert Panel 2019 addressed some of these challenges. Methods: Based on evidence in the literature and expert interviews, 19 statements were formulated for key challenges in the treatment of men with castration-sensitive and -resistant prostate cancer in clinical practice. A modified Delphi process was used to reach consensus among experts in the panel and develop clinical practice recommendations. Results: The majority of the panel preferred a risk-based stratification and recommended abiraterone or enzalutamide as first-line therapy for symptomatic chemotherapy naïve patients. Abiraterone is preferred over enzalutamide as a first-line treatment in these patients. However, the panel did not support the use of abiraterone in high risk lymph-node positive only (N+M0) or in non-metastatic (N0M0) patients. In select patients, low dose abiraterone with food may be used to optimize clinical outcomes. Androgen receptor gene splice variant status may be a useful guide to therapy. In addition, generic versions of approved therapies may improve access to treatment to a broader patient population. The choice of treatment, as well as sequencing are guided by both patient and disease characteristics, preferences, drug access, cost, and compliance. Conclusion: Expert recommendations are key to guidance for the optimal management of mPC. Appropriate choice, timing, and sequence of treatment options can help to tailor therapy to maximize outcomes in men with mPC.",
        "prism:coverDate": "2021-01-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85101563160",
        "subtypeDescription": "Review",
        "dc:creator": {"author": [{
            "ce:given-name": "Fabio Augusto Barros",
            "preferred-name": {
                "ce:given-name": "Fabio Augusto Barros",
                "ce:initials": "F.A.B.",
                "ce:surname": "Schutz",
                "ce:indexed-name": "Schutz F.A.B."
            },
            "@seq": "1",
            "ce:initials": "F.A.B.",
            "@_fa": "true",
            "ce:surname": "Schutz",
            "@auid": "35181986100",
            "author-url": "https://api.elsevier.com/content/author/author_id/35181986100",
            "ce:indexed-name": "Schutz F.A.B."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85101563160"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85101563160&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85101563160&origin=inward"
            }
        ],
        "prism:publicationName": "Therapeutic Advances in Medical Oncology",
        "source-id": "19700175160",
        "citedby-count": "1",
        "prism:volume": "13",
        "subtype": "re",
        "dc:title": "Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel",
        "openaccess": "1",
        "openaccessFlag": "true",
        "prism:doi": "10.1177/1758835920985464",
        "prism:issn": "17588359 17588340",
        "publishercopyright": "© The Author(s), 2021.",
        "dc:identifier": "SCOPUS_ID:85101563160",
        "dc:publisher": "SAGE Publications Inc."
    },
    "idxterms": null,
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "abiraterone"
        },
        {
            "@_fa": "true",
            "$": "chemotherapy"
        },
        {
            "@_fa": "true",
            "$": "docetaxel"
        },
        {
            "@_fa": "true",
            "$": "enzalutamide"
        },
        {
            "@_fa": "true",
            "$": "metastatic prostate cancer"
        }
    ]},
    "subject-areas": {"subject-area": [{
        "@_fa": "true",
        "$": "Oncology",
        "@code": "2730",
        "@abbrev": "MEDI"
    }]},
    "authors": {"author": [
        {
            "ce:given-name": "Fabio Augusto Barros",
            "preferred-name": {
                "ce:given-name": "Fabio Augusto Barros",
                "ce:initials": "F.A.B.",
                "ce:surname": "Schutz",
                "ce:indexed-name": "Schutz F.A.B."
            },
            "@seq": "1",
            "ce:initials": "F.A.B.",
            "@_fa": "true",
            "ce:surname": "Schutz",
            "@auid": "35181986100",
            "author-url": "https://api.elsevier.com/content/author/author_id/35181986100",
            "ce:indexed-name": "Schutz F.A.B."
        },
        {
            "ce:given-name": "Ekaphop",
            "preferred-name": {
                "ce:given-name": "Ekaphop",
                "ce:initials": "E.",
                "ce:surname": "Sirachainan",
                "ce:indexed-name": "Sirachainan E."
            },
            "@seq": "2",
            "ce:initials": "E.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60199578",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578"
            },
            "ce:surname": "Sirachainan",
            "@auid": "6602792356",
            "author-url": "https://api.elsevier.com/content/author/author_id/6602792356",
            "ce:indexed-name": "Sirachainan E."
        },
        {
            "ce:given-name": "Shanggar",
            "preferred-name": {
                "ce:given-name": "Shanggar",
                "ce:initials": "S.",
                "ce:surname": "Kuppusamy",
                "ce:indexed-name": "Kuppusamy S."
            },
            "@seq": "3",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60013665",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013665"
            },
            "ce:surname": "Kuppusamy",
            "@auid": "36115254700",
            "author-url": "https://api.elsevier.com/content/author/author_id/36115254700",
            "ce:indexed-name": "Kuppusamy S."
        },
        {
            "ce:given-name": "Nguyen Thi Thai",
            "preferred-name": {
                "ce:given-name": "Nguyen Thi Thai",
                "ce:initials": "N.T.T.",
                "ce:surname": "Hoa",
                "ce:indexed-name": "Hoa N.T.T."
            },
            "@seq": "4",
            "ce:initials": "N.T.T.",
            "@_fa": "true",
            "affiliation": {
                "@id": "100787418",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100787418"
            },
            "ce:surname": "Hoa",
            "@auid": "57222117474",
            "author-url": "https://api.elsevier.com/content/author/author_id/57222117474",
            "ce:indexed-name": "Hoa N.T.T."
        },
        {
            "ce:given-name": "Thitiya",
            "preferred-name": {
                "ce:given-name": "Thitiya",
                "ce:initials": "T.",
                "ce:surname": "Dejthevaporn",
                "ce:indexed-name": "Dejthevaporn T."
            },
            "@seq": "5",
            "ce:initials": "T.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60199578",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578"
            },
            "ce:surname": "Dejthevaporn",
            "@auid": "57202709168",
            "author-url": "https://api.elsevier.com/content/author/author_id/57202709168",
            "ce:indexed-name": "Dejthevaporn T."
        },
        {
            "ce:given-name": "Badrulhisham",
            "preferred-name": {
                "ce:given-name": "Badrulhisham",
                "ce:initials": "B.",
                "ce:surname": "Bahadzor",
                "ce:indexed-name": "Bahadzor B."
            },
            "@seq": "6",
            "ce:initials": "B.",
            "@_fa": "true",
            "affiliation": {
                "@id": "121444563",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/121444563"
            },
            "ce:surname": "Bahadzor",
            "@auid": "54787296900",
            "author-url": "https://api.elsevier.com/content/author/author_id/54787296900",
            "ce:indexed-name": "Bahadzor B."
        },
        {
            "ce:given-name": "Vu Quang",
            "preferred-name": {
                "ce:given-name": "Vu Quang",
                "ce:initials": "V.Q.",
                "ce:surname": "Toan",
                "ce:indexed-name": "Toan V.Q."
            },
            "@seq": "7",
            "ce:initials": "V.Q.",
            "@_fa": "true",
            "affiliation": {
                "@id": "100787418",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100787418"
            },
            "ce:surname": "Toan",
            "@auid": "57222119567",
            "author-url": "https://api.elsevier.com/content/author/author_id/57222119567",
            "ce:indexed-name": "Toan V.Q."
        },
        {
            "ce:given-name": "Phichai",
            "preferred-name": {
                "ce:given-name": "Phichai",
                "ce:initials": "P.",
                "ce:surname": "Chansriwong",
                "ce:indexed-name": "Chansriwong P."
            },
            "@seq": "8",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60199578",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578"
            },
            "ce:surname": "Chansriwong",
            "@auid": "37007308200",
            "author-url": "https://api.elsevier.com/content/author/author_id/37007308200",
            "ce:indexed-name": "Chansriwong P."
        },
        {
            "ce:given-name": "Adlinda",
            "preferred-name": {
                "ce:given-name": "Adlinda",
                "ce:initials": "A.",
                "ce:surname": "Alip",
                "ce:indexed-name": "Alip A."
            },
            "@seq": "9",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60013665",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013665"
            },
            "ce:surname": "Alip",
            "@auid": "56495291900",
            "author-url": "https://api.elsevier.com/content/author/author_id/56495291900",
            "ce:indexed-name": "Alip A."
        },
        {
            "ce:given-name": "Nguyen Thi Minh",
            "preferred-name": {
                "ce:given-name": "Nguyen Thi Minh",
                "ce:initials": "N.T.M.",
                "ce:surname": "Hue",
                "ce:indexed-name": "Hue N.T.M."
            },
            "@seq": "10",
            "ce:initials": "N.T.M.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60071389",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071389"
            },
            "ce:surname": "Hue",
            "@auid": "57222128661",
            "author-url": "https://api.elsevier.com/content/author/author_id/57222128661",
            "ce:indexed-name": "Hue N.T.M."
        },
        {
            "ce:given-name": "Napa",
            "preferred-name": {
                "ce:given-name": "Napa",
                "ce:initials": "N.",
                "ce:surname": "Parinyanitikul",
                "ce:indexed-name": "Parinyanitikul N."
            },
            "@seq": "11",
            "ce:initials": "N.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60022183",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183"
            },
            "ce:surname": "Parinyanitikul",
            "@auid": "36554719100",
            "author-url": "https://api.elsevier.com/content/author/author_id/36554719100",
            "ce:indexed-name": "Parinyanitikul N."
        },
        {
            "ce:given-name": "Ai Lian",
            "preferred-name": {
                "ce:given-name": "Ai Lian",
                "ce:initials": "A.L.",
                "ce:surname": "Tan",
                "ce:indexed-name": "Tan A.L."
            },
            "@seq": "12",
            "ce:initials": "A.L.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60103837",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60103837"
            },
            "ce:surname": "Tan",
            "@auid": "55585808300",
            "author-url": "https://api.elsevier.com/content/author/author_id/55585808300",
            "ce:indexed-name": "Tan A.L."
        },
        {
            "ce:given-name": "Vu Dinh Khanh",
            "preferred-name": {
                "ce:given-name": "Vu Dinh Khanh",
                "ce:initials": "V.D.K.",
                "ce:surname": "Hoang",
                "ce:indexed-name": "Hoang V.D.K."
            },
            "@seq": "13",
            "ce:initials": "V.D.K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "107981430",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/107981430"
            },
            "ce:surname": "Hoang",
            "@auid": "57222132081",
            "author-url": "https://api.elsevier.com/content/author/author_id/57222132081",
            "ce:indexed-name": "Hoang V.D.K."
        },
        {
            "ce:given-name": "Piyawan",
            "preferred-name": {
                "ce:given-name": "Piyawan",
                "ce:initials": "P.",
                "ce:surname": "Tienchaiananda",
                "ce:indexed-name": "Tienchaiananda P."
            },
            "@seq": "14",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60005255",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005255"
            },
            "ce:surname": "Tienchaiananda",
            "@auid": "56705450700",
            "author-url": "https://api.elsevier.com/content/author/author_id/56705450700",
            "ce:indexed-name": "Tienchaiananda P."
        },
        {
            "ce:given-name": "Sai Naga Deepak",
            "preferred-name": {
                "ce:given-name": "Sai Naga Deepak",
                "ce:initials": "S.N.D.",
                "ce:surname": "Chinchapattanam",
                "ce:indexed-name": "Chinchapattanam S.N.D."
            },
            "@seq": "15",
            "ce:initials": "S.N.D.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60017484",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017484"
            },
            "ce:surname": "Chinchapattanam",
            "@auid": "57222123023",
            "author-url": "https://api.elsevier.com/content/author/author_id/57222123023",
            "ce:indexed-name": "Chinchapattanam S.N.D."
        },
        {
            "ce:given-name": "Amit",
            "preferred-name": {
                "ce:given-name": "Amit",
                "ce:initials": "A.",
                "ce:surname": "Garg",
                "ce:indexed-name": "Garg A."
            },
            "@seq": "16",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60017484",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017484"
            },
            "ce:surname": "Garg",
            "@auid": "57192432999",
            "author-url": "https://api.elsevier.com/content/author/author_id/57192432999",
            "ce:indexed-name": "Garg A."
        }
    ]}
}}